Advising clients in a range of complex deals, Salmon made partner at Davis Polk last year after joining the firm straight out of law school about a decade ago.
Salmon led a Davis Polk team advising the syndicate of underwriters that helped Aimmune Therapeutics Inc. in its initial public offering. The IPO was one of the largest by a California company last year, according to Renaissance Capital LLC, an IPO-tracking firm.
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In
Enewsletter Sign-up
By using our website, you agree to our use of cookies in accordance with our cookie policy. You can learn more about how we use cookies by reviewing our Privacy Policy
here.